DNA is in our blood
Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. Our mission is to change the management of disease worldwide by using information gained from a simple blood draw to proactively inform treatment.
Next-generation cell-free DNA testing
Through our next-generation, cfDNA technology platform, we’ve pioneered noninvasive blood-based testing in the fields of women’s health, oncology, and organ health.
Focused on experience and support
At Natera, we’re building an entirely new way to manage genetic testing: in the cloud. We’ve made it possible to virtually order tests, schedule mobile blood draws, access test results, and consult with genetic counselors — all with the click of a button. Our global footprint spans 90 countries worldwide, putting cfDNA testing within reach.
Our mission is personal
Applying clinical expertise, leading-edge cell-free DNA technology, and operational excellence to change the management of disease worldwide
Natera was born from a deeply personal desire to change the way disease was managed.
“In 2004, my sister gave birth to a son with Down Syndrome. He passed away six days after birth. It was a devastating experience for our entire family. I founded Natera because I believe all families deserve access to technologies that offer early detection of genetic disease.”
Since its founding, Natera has pushed the boundaries of testing management with a proven track record of scientific excellence and innovation.
|2004||Natera, Inc. is founded by Matthew Rabinowitz, Ph.D. and Jonathan Sheena, M. Eng|
|2009||Spectrum preimplantation genetic test introduced|
|2010||Anora miscarriage test (POC) introduced|
|2012||Horizon advanced carrier screening test introduced|
|2013||Panorama next-generation NIPT introduced|
|2015||Natera, Inc. holds Initial Public Offering (IPO)|
|2016||Natera and USCF collaborate on a study evaluating the use of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant patients|
|2017||Vistara single-gene NIPT introduced|
|2017||Signatera molecular residual disease (MRD) test introduced (Research Use Only)|
|2017||Study published in Nature shows early relapse detection in lung cancer using Natera’s circulating tumor DNA (ctDNA) technology|
|2018||Natera and Fox Chase Cancer Center collaborate on kidney cancer study using the Signatera RUO test|
|2018||Signatera RUO Test shown to detect molecular residual disease up to 2 years prior to clinical relapse and to predict treatment response in breast cancer|
|2019||Steve Chapman appointed CEO|
|2019||Signatera CLIA test introduced|
|2019||FDA grants breakthrough device designation to Natera’s Signatera test|
|2019||Panorama NIPT achieves 2 million test milestone|
|2019||Prospera donor-derived cell-free DNA (dd-cfDNA) transplant assessment test introduced|
|2020||Empower hereditary cancer test introduced|
|2020||Natera expands lab footprint with a facility in Austin, Texas|
|2020||Renasight kidney gene panel introduced|
|2020||Publication in Nature Cancer shows Signatera’s ability to evaluate tumor response to immunotherapy|